Results 11 to 20 of about 4,268 (199)

Promises and challenges: cabotegravir for preexposure prophylaxis [PDF]

Current Opinion in HIV and AIDS, 2022
PURPOSE OF REVIEW: Tenofovir-based oral PrEP has been effective in reducing population-level HIV incidence in multiple settings, although disparities remain.
Matthew A. Spinelli, Beatriz Grinsztejn, Landovitz, Raphael J, Grinsztejn, Beatriz, Raphael J. Landovitz, Spinelli, Matthew A   +5 more
core   +5 more sources

Multitasking Pharmacophores Support Cabotegravir-Based Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)

Molecules
Cabotegravir is an integrase strand transfer inhibitor (INSTI) for HIV treatment and prevention. Cabotegravir-based long-acting pre-exposure prophylaxis (PrEP) presents an emerging paradigm for infectious disease control. In this scheme, a combination of
Zheng Wan, Man Shi, Yanqing Gong, Massimo Lucci, Jinjin Li, Jiahai Zhou, Xiao-Liang Yang, Moreno Lelli, Xiao He, Jiafei Mao   +9 more
doaj   +2 more sources

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in SwitzerlandResearch in context [PDF]

The Lancet Regional Health. Europe
Summary: Background: The efficacy and tolerability of long-acting cabotegravir and rilpivirine were demonstrated in Phase III trials. However, low concentrations combined with other risk factors have been associated with an increased risk of virologic ...
Paul Thoueille, Susana Alves Saldanha, Fabian Schaller, Eva Choong, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F. Günthard, Katharina Kusejko, Bernard Surial, Hansjakob Furrer, Andri Rauch, Mathieu Rougemont, Pilar Ustero, Alexandra Calmy, Marcel Stöckle, Catia Marzolini, Caroline Di Benedetto, Enos Bernasconi, Patrick Schmid, Rein Jan Piso, Pascal Andre, François R. Girardin, Monia Guidi, Thierry Buclin, Laurent A. Decosterd   +25 more
doaj   +3 more sources

Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date

HIV/AIDS: Research and Palliative Care, 2016
Thomas Whitfield, Adele Torkington, Clare van Halsema North West Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK Abstract: Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and ...
Whitfield T, Torkington A, van Halsema C
doaj   +1 more source

Modelling the 5-Year Impact of Twice-Yearly Injectable Lenacapavir for HIV Pre-Exposure Prophylaxis in the United States. [PDF]

J Int AIDS Soc
Abstract Introduction The impact of pre‐exposure prophylaxis (PrEP) on the US HIV‐1 epidemic has not been fully maximized, potentially due to challenges in uptake, coverage, adherence and consistent use. Following the FDA (Food and Drug Adminstration) approval of twice‐yearly lenacapavir, epidemiological projections are needed to understand the ...
Moore M, Lee S, Matrajt L, Stansfield SE, Tao L, Yang J, Mezzio D, Jarrett J, Castro JC, Hsiao A, Zachry W, Dimitrov D.   +11 more
europepmc   +2 more sources

Long-Acting Therapeutics in Pediatric Health: Bridging Innovation and Access. [PDF]

Clin Pharmacol Ther
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Venkatasubramanian P, Archary M, Hawcutt DB, Daley R, Capparelli E, Olagunju A.   +5 more
europepmc   +2 more sources

Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa:a modelling study [PDF]

, 2023
BACKGROUND: Long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) is recommended by WHO as an additional option for HIV prevention in sub-Saharan Africa, but there is concern that its introduction could lead to an increase in integrase ...
Inzaule, Seth, Landovitz, Raphael J, Ripin, David, Bershteyn, Anna, Shahmanesh, Maryam, Stansfield, Sarah, Phillips, Andrew N, Dimitrov, Dobromir, Revill, Paul, Schapiro, Jonathan, Jordan, Michael, Radebe, Mopo, Paredes, Roger, Raizes, Elliot, Bansi-Matharu, Loveleen, Boily, Marie-Claude, Delany-Moretlwe, Sinead, Venter, Francois, Amole, Carolyn, HIV Modelling Consortium, Johnson, Cheryl, Cambiano, Valentina, Flexner, Charles, van Oosterhout, Joep J, Siedner, Mark J, Kripke, Katharine, Kuritzkes, Daniel, Schaefer, Robin, Taramusi, Isaac, Shafer, Robert, Lundgren, Jens D, Resar, Danielle, van de Vijver, David, Gupta, Ravindra K, Jenkins, Sarah, Warren, Mitchell, Smith, Jennifer, Meyer-Rath, Gesine   +37 more
core   +5 more sources

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. [PDF]

J Med Virol
ABSTRACT Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or ...
Boujamline S, Boschi C, Bes-Barlandier H, Tomei C, Menard A, Mokhtari S, Ravaux I, Belkhir Y, Neant N, Solas C, Colson P, Million M.   +11 more
europepmc   +2 more sources

Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials

Frontiers in Pharmacology, 2021
Objectives: To investigate the safety and pharmacokinetic profiles of long-acting injectable pre-exposure prophylaxis (LAI PrEP), notably cabotegravir (CAB-LA) and rilpivirine (RPV-LA), for the prevention of human immunodeficiency virus-1 (HIV-1 ...
Gilbert Lazarus, Vincent Kharisma Wangsaputra, Christianto, Melva Louisa, Vivian Soetikno, Raph L. Hamers, Raph L. Hamers, Raph L. Hamers   +7 more
doaj   +1 more source

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries

Journal of the International AIDS Society, 2023
Introduction Reductions in HIV acquisition have slowed, and the global community is significantly off track from global goals. Oral pre‐exposure prophylaxis (PrEP) alone cannot address the diverse needs of the millions of people at risk of HIV ...
Sarah Y. Jenkins, Danielle Resar, Zachary Panos, Alan Staple, Melynda Watkins, David Ripin, Carolyn Amole   +6 more
doaj   +1 more source